Competitive Landscape Of Top CRISPR Technology Companies

Report Overview

Our healthcare portfolio has been developing since our inception in 2014, wherein we have tracked numerous sub-domains and their R&D activities. We have actively been tracking genomics and genetic engineering space and have seen the evolution of these players over time. To help understand and highlight their development journey, we have made this special study that focuses on the top CRISPR technology companies.

CRISPR technology is being rapidly adopted in various domains of the life sciences industry due to its precision and efficiency in gene editing which has revolutionized research, allowing scientists to make highly targeted modifications with minimal off-target effects. The technology is relatively cost-effective compared to other gene editing methods such as Transcription Activator-Like Effector Nucleases (TALENs) or Zinc Finger Nucleases (ZFNs), making it accessible to a broader range of researchers and institutions. Furthermore, the growing demand for personalized medicine and innovative treatments for genetic disorders has sparked interest in CRISPR’s potential. As advancements in genomics and genetic engineering continue, the demand for sophisticated gene editing techniques like CRISPR technology is anticipated to grow rapidly.

Market Share Analysis for Top CRISPR Technology Product/Service Providers

The CRISPR technology industry features a diverse range of companies, from major industry leaders to innovative startups, each providing an array of products and services. As part of the research process, we have identified the key players operating in this market based on several parameters such as revenues, product portfolio, supply chain efficiency, and strategic initiatives, among others. We determined and analyzed the regional revenues of the key market players from annual reports and investor presentations and further identified the relevant business segments of these companies. We also performed exhaustive product mapping and estimated the product-specific revenues commanded by these players to perform a market share analysis.

During this process, we also conducted exhaustive secondary research through various data sources including research publications, white papers, press releases, and other authentic data sources to understand the key strategies adopted by these companies. Furthermore, we conducted primary interviews from both the supply side and demand side of the market to obtain insights and validate our findings. Besides this, we referred to our large repository of market reports for various sectors and subsectors within the biotechnology industry. The data obtained from primary interviews, secondary research, and our in-house database was triangulated and processed to derive the market share of key companies. The dataset was further validated by industry experts through telephonic interviews and questionnaire-based surveys.

Competitive Landscape: Top CRISPR Technology Companies Report Coverage

The CRISPR technology market is highly competitive, with leading companies like Thermo Fisher Scientific, Inc. and Merck KGaA offering a wide range of products and services. Furthermore, as companies like Cellecta, Origene Technologies, and other emerging innovators continue to advance in this field, competition within the industry is expected to increase further.

The report analyses the competitive landscape in this industry based on parameters mentioned below:

Pipeline Analysis for CRISPR-based Clinical Trials

The recent regulatory approval of Casgevy (exagamglogene autotemcel), a therapy for sickle cell disease and transfusion-dependent β-thalassemia, in November 2023 by UK’s regulatory authority has demonstrated CRISPR’s utility in commercial applications. This has led to a heightened interest in the development of novel CRISPR-based therapeutic and diagnostic solutions. The following figure shows the percentage of clinical trials investigating CRISPR-based solutions, by disease area, as of Q4 2023.

Despite the growing excitement however, the field faces significant challenges. Due to the economic downturn in the biotechnology industry following the COVID-19 pandemic, investors now demand quicker returns. This pressure is leading companies to focus on advancing clinical trials and rapidly bringing products to market. The financial pressure, coupled with the high costs of clinical trials, has caused companies to narrow their focus to the most advanced products instead of expanding their research or developing new treatments. This factor may limit the number of new trials being introduced in the CRISPR technology field. 

Competitive Analysis: Thermo Fisher Scientific, Inc.

Company Overview:

• Headquarter: Massachusetts, U.S.

• Establishment Year: 1956

• Employee Strength (2023): 122,000

• Business Overview: Thermo Fisher Scientific, Inc. is a key player in the life sciences and biotechnology sectors, recognized for its comprehensive range of products and services that support scientific research and clinical applications. The company specializes in areas such as molecular biology, cell culture, genomics, and offers cutting-edge tools, including reagents and instrumentation. It caters to a wide spectrum of end-users, from academic researchers to pharmaceutical companies. Thermo Fisher Scientific's CRISPR portfolio includes various tools and reagents, such as CRISPR-Cas9 nucleases, guide RNA libraries, and cell engineering services, designed to facilitate precise gene editing across various applications. The company’s extensive portfolio has solidified its position as a key player in the CRISPR technology industry.

SWOT Analysis:

Financial Performance:

List of top 15 CRISPR technology product/service providers:

• Thermo Fisher Scientific

• Horizon Discovery

• Merck KGaA

• Synthego

• Danaher

• Agilent Technologies

• GenScript

• Takara Bio

• Origene Technologies

• New England Biolabs (NEB)

• Cellecta

• Qiagen

• Santa Cruz Biotechnology

• Addgene

• OZ Biosciences

List of top 15 CRISPR technology therapeutics companies:

• CRISPR Therapeutics

• Editas Medicine

• Intellia Therapeutics

• Caribou Biosciences

• Beam Therapeutics

• Graphite Bio

• Precision BioSciences

• Verve Therapeutics

• Poseida Therapeutics

• EdiGene

• Passage Bio

• Allogene Therapeutics

• HuidaGene Therapeutics

• Prime Medicine

• Excision Biotherapeutics